Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Interference of the gut microbiota with the treatment of parkinson’s disease
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Interference of the gut microbiota with the treatment of parkinson’s disease
Gastroenterology

Interference of the gut microbiota with the treatment of parkinson’s disease

Drug interaction
Neurology Gastroenterology

Some bacterial species of the gut microbiota are an obstacle to the first-line treatment of Parkinson’s disease. A research team characterized and identified a molecule that is able to inhibit this interference.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail
Photo : Interference of the gut microbiota with the treatment of parkinson’s disease

About this article

Created 03 September 2019
Updated 04 March 2022

Parkinson’s disease is a neurodegenerative disease affecting more than 1% of people over 60 worldwide. Its treatment produces very heterogeneous results in terms of efficacy and side-effects, depending on patients. Based on a study published in the journal Science, the gut microbiota could be the cause behind this variability.

Treatment with heterogeneous effects

The current treatment is based on a drug, levodopa (L-dopa), which, when metabolized in the brain, replaces dopamine that neural cells do not produce anymore. Problem: a significant part of L-dopa is transformed into dopamine in the intestines; however dopamine thus produced at the peripheral level cannot cross the blood-brain barrier and cannot reach the brain, which not only reduces the treatment’s efficacy but may also generate severe side-effects (gastrointestinal disorders and cardiac arrhythmias). Therefore, another molecule, carbidopa, is administered concomitantly in order to block this metabolization process: despite that, up to 56% of L-dopa does not reach the brain.

Interference of the gut microbiota

Although the interference of the gut microbiota with treatment’s efficacy was already suspected, its mechanism of action remained unclear until this study. The exploration of the bacterial metagenome first helped identify a species–Enterococcus faecalis–with tyrosine decarboxylase activity that degrades L-dopa into dopamine. The researchers then brought to light the conversion of dopamine into m-tyramine under the action of another enzyme–a molybdenum-dependent dehydroxylase–present in Eggerthella lenta. Differences in these microbial activities could potentially contribute to heterogeneous responses to L-dopa observed in patients, thus explaining its reduced efficacy and its side-effects observed in some of them.

Blocking the gut degradation of L-dopa

The researchers then tried to understand why carbidopa proved hardly effective to prevent the gut metabolization of L-dopa. Their conclusion was that although this molecule is indeed able to inhibit human decarboxylase involved in the metabolization of L-dopa, it turned out to have no effect on the decarboxylase present in E. faecalis in vivo. They then identified an inhibitor ( (sidenote: AFMT (S)-α-fluoromethyltyrosine ) ) able to block the bacterial enzyme. The last phase of their works showed that the administration of standard treatment (L-dopa + carbidopa) combined with AFMT to (sidenote: Gnotobiotic mice refers to laboratory animals in which only certain known strains of microorganisms are present )  colonized by E. faecalis, increases the serum concentration of L-dopa, thus demonstrating in vivo the inhibition of L-dopa degradation by the gut microbiota. This is (sidenote: Professor E. Balskus received the 2019 International Award of the Biocodex Microbiota Foundation for these works and as support for upcoming projects on this subject matter )  that could open the way to new therapies targeting the microbiota.

Sources

Maini Rekdal V, Bess EN, Bisanz JE, et al. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445):eaau6323.

 

Tags
Antiparkinson Dysbiosis

en_view en_sources

    Created 03 September 2019
    Updated 04 March 2022

    About this article

    To know more about this topic.

    Main topic

    Drug interaction

    Medical practice

    Neurology Gastroenterology

    Content type

    News
    Gastroenterology

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more

    Everything you need to know about Irritable Bowel Syndrome (IBS)

    Accrediting training, infographics, expert’s video, thematic folder, news… Biocodex Microbiota Institute pr...

    Find out more

    Gut Microbiota #17

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Gut Microbiota # 16

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Highlights from the UEGW

    By Dr. Lucas WautersGastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

    Find out more

    The Gut-Brain axis

    By Pr. Sarkis K. Mazmanian, John W. Bostick, Nadia SuryawinataBiology and Biological Engineering, Californi...

    Find out more

    Continue reading

    News
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    The psychobiotic diet: modulating gut microbiota to reduce stress
    13.02.2023

    The psychobiotic diet: modulating gut microbiota to reduce stress

    Read the article
    30.01.2023

    Schizophrenia and aggressive behavior: what involvement of the intestinal microbiota?

    Read the article
    23.01.2023

    Idiopathic urethritis in men: new infectious etiologies?

    Read the article
    13.01.2023

    Insomnia in seniors: a link with the gut microbiota

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo